News and Media

Latest News Release
04/13/2021

Cardinal Health (NYSE: CAH) was awarded a $57.8 million contract, including options that if exercised by the U.S. Department of Health and Human Services (HHS) could reach $91.6 million, for the...

Top feature box IMAGE ONLY - COMPANY NEWS

Company News

Theranostics: Reimagining the standard of care
06/03/2021

By Tiffany Olson, president of Nuclear & Precision Health Solutions at Cardinal Health

From HealthCare Business News magazine:

Precision medicine is an area of healthcare that targets treatment for a well-defined patient population, with the goal of improving safety, efficacy and outcomes. Theranostics take the concept of precision medicine a step further, targeting care for individual patients. In fact, the field has been called the epitome of personalized medicine. Simply put, theranostics combine a diagnostic radiopharmaceutical and therapeutic radiopharmaceutical, which are tailored to the patient at the cellular level. 

https://www.dotmed.com/news/story/54838?utm_campaign=MagLink&utm_source=DMBusiness&utm_medium=print

More Company News
06/17/2021

By Victor Crawford, CEO of the Pharmaceutical Segment at Cardinal Health

06/17/2021

In response to Ohio Governor Mike DeWine's request that business leaders help increase vaccination rates, four Ohio Managed Care Organizations (MCOs) are partnering with Outcomes™ to leverage...

06/16/2021

By Steve Mason, CEO of the Medical Segment at Cardinal Health I recently joined a diverse group of colleagues in a panel discussion about what it means to be an advocate for gender, racial and...

06/10/2021

Cardinal Health (NYSE: CAH) today announced that LYMPHOSEEK® (technetium Tc 99m tilmanocept) injection – the first and only radiopharmaceutical agent specifically designed for targeted...

View all company news »

* Required Fields